Once they sign the licence for the clinical development of Progenza in Japan it will trigger the first US$5m milestone payment from AGC and add any upfront from that licencee they get and they will share with AGC.
Hopefully not too far away now, the more I read on AGC the more I like, especially their newly formed US arm and changing to AGC Inc. their plans to 2020 are fantastic and we are certainly partnered with a well established, well equipped and massive company to go forward with!
RGS Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
